Introduction of Somatrogon in Pediatric Growth Hormone Deficiency: Real-World Insights From a National Survey of Pediatric Endocrinologists
Authors' conclusion
This survey revealed heterogenous long-acting growth hormone prescribing behaviors among pediatric endocrinologists during the introductory period of its availability. The findings call for continued search for real-world evidence and refined clinical guidelines to promote effective and safe integration of this promising therapy into clinical practice.
Study context
- Population
- Pediatric endocrinologists in Israel prescribing somatrogon (introduced July 2024) for pediatric GHD; survey May–June 202565 responded (63.7%)
- Participants
- 102 participants
- Outcome
- Somatrogon prescribing patterns, barriers and attitudes
Methodological detailsnationwide survey, structured 19-item questionnaire
- Nationwide survey
- Structured 19-item questionnaire
Main finding
As reported in the abstract
- Patients reported treated with somatrogon
- at least 874
- Respondents who transitioned over one-half of their patients from daily GH
- 33 (50.8%)
- Most common initial dose 0.66 mg/kg/wk
- 54.8%
- Reluctant to prescribe for patients with oncologic history
- 91.9%
- Reluctant to prescribe for patients with genetic syndromes
- 66.1%
- Long-term safety concerns as primary barrier to broader adoption
- 77.4%
- Reversion to daily therapy recalled (at least one case)
- 59.7%
Observational data: associations, not effects.
Safety
Adverse effects reported by respondents
- Injection site reactions, most frequently reported adverse effect
- 62.9%
- Marked injection site lipoatrophy after repeated injections into the same region
- 1 case
Original publication
Introduction of Somatrogon in Pediatric Growth Hormone Deficiency: Real-World Insights From a National Survey of Pediatric Endocrinologists. Endocr Pract. Published 13 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →